Monoclonal Antibody Treatment - REGEN-COV
Geared to reduce the worst symptoms of COVID-19 and prevent hospitalization for people with mild to moderate cases.
What is REGEN-COV?
REGEN‑COV is an investigational medicine used in adults and adolescents (12 years of age and older who weigh at least 88 pounds (40 kg)) who are at high risk for severe COVID‑19, including hospitalization or death for:
- treatment of mild to moderate symptoms of COVID-19
- post-exposure prophylaxis of COVID-19 in persons who are:
- not fully vaccinated against COVID-19 (Individuals are considered to be fully vaccinated 2 weeks after their second vaccine dose in a 2-dose series [such as the Pfizer or Moderna vaccines], or 2 weeks after a single-dose vaccine [such as Johnson & Johnson’s Janssen vaccine]), or,
- are not expected to build up enough of an immune response to the complete COVID-19 vaccination (for example, someone with immunocompromising conditions, including someone who is taking immunosuppressive medications), and
- have been exposed to someone who is infected with SARS-CoV-2. Close contact with someone who is infected with SARS-CoV-2 is defined as being within 6 feet for a total of 15 minutes or more, providing care at home to someone who is sick, having direct physical contact with the person (hugging or kissing, for example), sharing eating or drinking utensils, or being exposed to respiratory droplets from an infected person (sneezing or coughing, for example). For additional details, go to https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/quarantine.html, or
- someone who is at high risk of being exposed to someone who is infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (for example, nursing homes, prisons)
REGEN‑COV is investigational because it is still being studied. There is limited information known about the safety and effectiveness of using REGEN‑COV to treat people with COVID‑19 or to prevent COVID-19 in people who are at high risk of being exposed to someone who is infected with SARS-CoV-2. REGEN-COV is not authorized for pre-exposure prophylaxis for the prevention of COVID-19.
The FDA has authorized the emergency use of REGEN‑COV for the treatment of COVID‑19 and the post-exposure prevention of COVID-19 under an Emergency Use Authorization (EUA).
What to Expect
Once your appointment is scheduled, arrive at the North Idaho Fairgrounds and park in the designated spots. WAIT IN YOUR VEHICLE Our staff will call you and then escort you back to the clinic. The treatment is provided on an outpatient basis via four subcutaneous injections. Patients receiving the injections will be observed by medical professionals for 1-Hour prior to leaving the center.
REGEN-COV, a combination monoclonal antibody therapy, has been authorized under the FDA’s emergency use authorization. Monoclonal antibodies work by targeting the coronavirus spike protein, blocking the virus from entering your body's cells, and stopping the infection from spreading.
Monoclonal antibodies are free to patients and there have been almost no side effects. The treatment is provided on an outpatient basis via four subcutaneous injections. Patients receiving the injections will be observed by medical professionals for an hour before being allowed to leave the center.
“This treatment has been shown to be most effective when patients receive it as soon as possible after testing positive for COVID-19,” said Dr. Peter Purrington, Chief Clinical Officer for Heritage Health.
“It can help reduce severe symptoms and hospitalization. Many patients who have received this treatment have experienced improvement in symptoms shortly after receiving it.”
Although REGEN-COV is also indicated for patients exposed to COVID and have high-risk health conditions as Post-Exposure Prophylaxis, due to limited supplies of medication the treatment is currently only available for patients with a positive COVID test and mild to moderate COVID symptoms.
The antibody treatment is not a cure for COVID-19 nor a replacement for vaccination. If you have mild to moderate COVID symptoms and a positive COVID test, contact your primary care provider to see if monoclonal antibody treatment is right for you.
To schedule an appointment, call:
Frequently Asked Questions
Do not take REGEN-COV if you have had a severe allergic reaction to REGEN-COV.
Tell your healthcare provider about all of your medical conditions, including if you:
- Have any allergies
- Have had a severe allergic reaction including anaphylaxis to REGEN-COV previously
- Have received a COVID-19 vaccine
- Have any serious illnesses
- Are pregnant or plan to become pregnant
- Are breastfeeding or plan to breastfeed
- Are taking any medications (prescriptions, over-the-counter drugs, vitamins, and herbal products)
REGEN-COV consists of two investigational medicines, casirivimab, and imdevimab, given together at the same time through a vein (intravenous or IV) or injected in the tissue just under the skin (subcutaneous injections). Your healthcare provider will determine the most appropriate way for you to be given REGEN-COV.
- Treatment: If you are receiving an intravenous infusion, the infusion will take 20 to 50 minutes or longer. Your healthcare provider will determine the duration of your infusion.
- If your healthcare provider determines that you are unable to receive REGEN-COV as an intravenous infusion which would lead to a delay in treatment, then as an alternative, REGEN-COV can be given in the form of subcutaneous injections. If you are receiving subcutaneous injections, your dose will be provided as multiple injections given in separate locations around the same time.
- Post-exposure prevention: If you are receiving subcutaneous injections, your dose will be provided as multiple injections given in separate locations around the same time. If you are receiving an intravenous infusion, the infusion will take 20 to 50 minutes or longer.
- After the initial dose, if your healthcare provider determines that you need to receive additional doses of REGEN-COV for ongoing protection, the additional intravenous or subcutaneous doses would be administered monthly.
Possible side effects of REGEN-COV are:
- Allergic reactions: Allergic reactions can happen during and after infusion or injection of REGEN-COV. Tell your healthcare provider right away if you get any of the following signs and symptoms of allergic reactions: fever, chills, nausea, headache, shortness of breath, low or high blood pressure, rapid or slow heart rate, chest discomfort or pain, weakness, confusion, feeling tired, wheezing, swelling of your lips, face, or throat, rash including hives, itching, muscle aches, feeling faint, dizziness, and sweating. These reactions may be severe or life-threatening.
- Worsening symptoms after treatment: You may experience new or worsening symptoms after infusion, including fever, difficulty breathing, rapid or slow heart rate, tiredness, weakness, or confusion. If these symptoms occur, contact your healthcare provider or seek immediate medical attention as some of these symptoms have required hospitalization. It is unknown if these symptoms are related to treatment or are due to the progression of COVID-19.
The side effects of getting any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site. The side effects of getting any medicine by subcutaneous injection may include pain, bruising of the skin, soreness, swelling, and possible infection at the injection site.
These are not all the possible side effects of REGEN-COV. Not a lot of people have been given REGEN-COV. Serious and unexpected side effects may happen. REGEN-COV is still being studied, so it is possible that all of the risks are not known at this time.
It is possible that REGEN-COV could interfere with your body’s own ability to fight off a future infection of SARS-CoV-2. Similarly, REGEN-COV may reduce your body’s immune response to a vaccine for SARS-CoV-2. Specific studies have not been conducted to address these possible risks. Talk to your healthcare provider if you have any questions.
Even if you’ve received a COVID-19 vaccine, you can still receive REGEN-COV if your doctor thinks it is appropriate. Use of REGEN-COV does not replace vaccination against COVID-19.
The CDC recommends 90 days between monoclonal antibody treatment and COVID-19 vaccination, but there are other things to consider in determining when to receive the vaccine.
Talk to your doctor about when you should receive the COVID-19 vaccine if you have received REGEN-COV.
Use of REGEN-COV does not replace vaccination against COVID-19. REGEN-COV may reduce your body’s immune response to a vaccine for SARS-CoV-2. Specific studies have not been conducted to address these possible risks.